The Effect of Intravitreal Erythropoietin Injection for Refractive Diabetic Macular Edema
|ClinicalTrials.gov Identifier: NCT03821168|
Recruitment Status : Unknown
Verified December 2018 by Zahra Rabbani Khah, Shahid Beheshti University of Medical Sciences.
Recruitment status was: Recruiting
First Posted : January 29, 2019
Last Update Posted : February 5, 2019
after advent of RD photoreceptor degeneration Occurred. This process appears as a incredible and progressive event that will not stop till reattachment of RPE and neurosensory retina happened .
Process of degeneration begins from first hours of RD establishment Neuroprotection of photoreceptor following RD is a novel and debatable discussion encountered in recent years .
How to stop this phenomena and neuroprotective agent role in this issue are a new interest of researches.
In the study investigators are planning to perform a clinical trial to demonstrate the minocycline neuroprotective effect in a double blind design as this impact has been implicated previously in a animal study.
|Condition or disease||Intervention/treatment||Phase|
|Refractory Diabetic Macular Edema||Drug: injection of bevacizumab and erythropoietin Drug: injection of bevacizumab||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||58 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||The Effect of Intravitreal Erythropoietin Injection for Refractive Diabetic Macular Edema|
|Estimated Study Start Date :||March 1, 2019|
|Estimated Primary Completion Date :||April 1, 2019|
|Estimated Study Completion Date :||October 1, 2019|
Active Comparator: intravitreal injection of bevacizumab and erythropoietin
Drug: injection of bevacizumab and erythropoietin
injection of bevacizumab and erythropoietin
Active Comparator: intravitreal injection of bevacizumab
Drug: injection of bevacizumab
under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness
- best corrected visual acuity [ Time Frame: 1 month ]Snellen chart
- Optical coherence tomography [ Time Frame: 1 month ]Optical coherence tomography
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03821168
|Contact: Morteza Entezari, MDemail@example.com|
|Iran, Islamic Republic of|
|Ophthalmic Research Center||Recruiting|
|Tehran, Iran, Islamic Republic of|
|Contact: Morteza Entzari, MD 009822591616 firstname.lastname@example.org|